Aligos Therapeutics Inc
ALGS7.590USD
+0.130+1.74%
交易中 （美东）报价延迟15分钟
52.48M总市值
亏损市盈率 TTM
关于 Aligos Therapeutics Inc 公司
Aligos Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发新型疗法，以满足肝脏和病毒疾病中未满足的医疗需求。该公司发现并开发代谢功能障碍相关脂肪性肝炎 (MASH) 和具有高度未满足医疗需求的病毒（例如慢性乙型肝炎 (CHB) 和冠状病毒）的疗法。其用于 MASH 的高级候选药物是 ALG-055009，一种小分子甲状腺激素受体 β (THR-β) 激动剂。该公司还在推进用于 MASH 的寡核苷酸项目。该公司正在开发一系列差异化的 CHB 候选药物，包括一种导致产生空病毒衣壳 (CAM-E) 的小分子衣壳组装调节剂和程序性细胞死亡配体 1 (PD-1/PD-L1) 相互作用的小分子抑制剂。其第三个重点领域是开发具有泛冠状病毒抗病毒活性的候选药物。其管道包括 ALG-055009、ALG-000184、ALG-125755 和 ALG-097558。
公司简介
公司代码ALGS
公司名称Aligos Therapeutics Inc
上市日期Oct 16, 2020
CEODr. Lawrence M. Blatt, Ph.D.
员工数量70
证券类型Ordinary Share
年结日Oct 16
公司地址One Corporate Dr., 2Nd Floor
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94080
电话18004666059
网址https://www.aligos.com/
公司代码ALGS
上市日期Oct 16, 2020
CEODr. Lawrence M. Blatt, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.82K
-1.34%
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
15.76K
-0.01%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
3.61K
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Margarita Chavez, J.D.
Ms. Margarita Chavez, J.D.
Independent Director
Independent Director
--
--
Dr. Hardean E. Achneck
Dr. Hardean E. Achneck
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Dr. Heather Preston, M.D.
Dr. Heather Preston, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.82K
-1.34%
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
15.76K
-0.01%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
3.61K
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Adage Capital Management, L.P.
8.75%
Deep Track Capital LP
8.36%
Roche Holding AG
8.30%
Alyeska Investment Group, L.P.
7.75%
Woodline Partners LP
5.93%
Other
60.91%
持股股东
持股股东
占比
Adage Capital Management, L.P.
8.75%
Deep Track Capital LP
8.36%
Roche Holding AG
8.30%
Alyeska Investment Group, L.P.
7.75%
Woodline Partners LP
5.93%
Other
60.91%
股东类型
持股股东
占比
Hedge Fund
44.95%
Investment Advisor
8.84%
Holding Company
8.30%
Investment Advisor/Hedge Fund
4.69%
Research Firm
3.41%
Individual Investor
2.14%
Venture Capital
0.19%
Other
27.47%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
98
3.84M
72.33%
+949.10K
2025Q1
107
3.92M
73.74%
+933.68K
2024Q4
102
2.24M
64.56%
-201.23K
2024Q3
108
2.31M
72.88%
-178.35K
2024Q2
119
2.51M
80.85%
+118.52K
2024Q1
173
2.47M
81.48%
-70.94K
2023Q4
186
2.43M
84.05%
+688.78K
2023Q3
190
1.29M
80.24%
-480.15K
2023Q2
195
1.32M
81.61%
-477.61K
2023Q1
201
1.36M
85.00%
-395.08K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Adage Capital Management, L.P.
465.00K
8.75%
+140.00K
+43.08%
Mar 31, 2025
Deep Track Capital LP
444.11K
8.36%
+200.00K
+81.93%
Mar 31, 2025
Roche Holding AG
441.04K
8.3%
-1.00
-0.00%
Mar 06, 2025
Alyeska Investment Group, L.P.
412.00K
7.75%
+412.00K
--
Mar 31, 2025
Woodline Partners LP
315.38K
5.93%
+315.38K
--
Mar 31, 2025
Heights Capital Management, Inc.
241.50K
4.54%
+241.50K
--
Mar 31, 2025
Hudson Bay Capital Management LP
241.50K
4.54%
+241.50K
--
Mar 31, 2025
Sio Capital Management, LLC
180.72K
3.4%
+180.72K
--
Mar 31, 2025
BofA Global Research (US)
154.50K
2.91%
+154.22K
+54111.58%
Mar 31, 2025
Tang Capital Management, LLC
141.13K
2.66%
+141.13K
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Schwab U.S. Small-Cap ETF
0%
Schwab U.S. Broad Market ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Schwab U.S. Small-Cap ETF
占比0%
Schwab U.S. Broad Market ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
iShares Micro-Cap ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
公告日期
类型
比率
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
Aug 15, 2024
Merger
25<1
